Subcutaneous(SC) Abatacept + Methotrexate
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis (RA)
Conditions
Rheumatoid Arthritis (RA)
Trial Timeline
Aug 1, 2016 → Dec 1, 2017
NCT ID
NCT02722694About Subcutaneous(SC) Abatacept + Methotrexate
Subcutaneous(SC) Abatacept + Methotrexate is a phase 3 stage product being developed by Bristol Myers Squibb for Rheumatoid Arthritis (RA). The current trial status is unknown. This product is registered under clinical trial identifier NCT02722694. Target conditions include Rheumatoid Arthritis (RA).
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02722694 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Rheumatoid Arthritis (RA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tilmanocept | Navidea Biopharmaceuticals | Phase 1 | 25 |
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| Baricitinib + TNF Inhibitor | Eli Lilly | Approved | 85 |
| CT-P17 SC AI (adalimumab) | Celltrion | Phase 3 | 77 |
| Remsima IV + Remsima SC | Celltrion | Pre-clinical | 23 |
| CT-P13 + Remicade | Celltrion | Phase 3 | 77 |
| CT-P47 + EU-approved RoActemra | Celltrion | Phase 3 | 77 |
| Infliximab | Celltrion | Phase 3 | 77 |
| CT-P13 SC Auto-Injector + Placebo Auto-Injector | Celltrion | Phase 3 | 77 |
| Rituximab, MTX, folic acid | Celltrion | Phase 1 | 33 |
| CT-P10 + Rituxan + MabThera | Celltrion | Phase 3 | 77 |
| CT-P47 AI (tocilizumab) + CT-P47 PFS (tocilizumab) | Celltrion | Phase 3 | 77 |
| CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 + CT-P13 | Celltrion | Phase 3 | 77 |
| rituximab | Celltrion | Phase 1 | 33 |
| CT-P17 SC + Humira SC | Celltrion | Phase 3 | 77 |
| Adalimumab | Celltrion | Pre-clinical | 23 |
| Infliximab | Celltrion | Phase 3 | 77 |